WO2005047414A1 - アレルゲン分解剤、および抗アレルゲン羽毛 - Google Patents
アレルゲン分解剤、および抗アレルゲン羽毛 Download PDFInfo
- Publication number
- WO2005047414A1 WO2005047414A1 PCT/JP2004/004445 JP2004004445W WO2005047414A1 WO 2005047414 A1 WO2005047414 A1 WO 2005047414A1 JP 2004004445 W JP2004004445 W JP 2004004445W WO 2005047414 A1 WO2005047414 A1 WO 2005047414A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- metal phthalocyanine
- allergen
- formula
- salt
- feather
- Prior art date
Links
Classifications
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M11/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising
- D06M11/58—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising with nitrogen or compounds thereof, e.g. with nitrides
- D06M11/59—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising with nitrogen or compounds thereof, e.g. with nitrides with ammonia; with complexes of organic amines with inorganic substances
- D06M11/62—Complexes of metal oxides or complexes of metal salts with ammonia or with organic amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B68—SADDLERY; UPHOLSTERY
- B68G—METHODS, EQUIPMENT, OR MACHINES FOR USE IN UPHOLSTERING; UPHOLSTERY NOT OTHERWISE PROVIDED FOR
- B68G3/00—Treating materials to adapt them specially as upholstery filling
- B68G3/08—Preparation of bed feathers from natural feathers
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K3/00—Materials not provided for elsewhere
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M13/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment
- D06M13/50—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with organometallic compounds; with organic compounds containing boron, silicon, selenium or tellurium atoms
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M19/00—Treatment of feathers
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M2101/00—Chemical constitution of the fibres, threads, yarns, fabrics or fibrous goods made from such materials, to be treated
- D06M2101/02—Natural fibres, other than mineral fibres
- D06M2101/10—Animal fibres
- D06M2101/12—Keratin fibres or silk
Definitions
- the present invention relates to a drug which decomposes an allergen using a metal phthalocyanine derivative as an active principal, a method for decomposing an allergen using the drug, and an anti-allergen feather carrying a metal phthalocyanine derivative. It is related. Background art
- Allergic symptoms are caused when allergens enter the human body through the skin, respiratory tract, or digestive tract, and are induced by the innate antigen-antibody reaction of the human, causing chemical mediators such as histamine and leukotriene to enter the body. Because of the release of free oxygen and the generation of reactive oxygen, secondary symptoms such as fever, rash, pruritus, vomiting, and rhinitis may occur. Such allergic symptoms occur depending on the combination of the type of allergen and the constitution of each individual human.
- Allergens are used as components of mites, their dead bodies and excrement, pollen of cedar, ragweed, power moths, bacteria, molds, eggs, milk, fish and shellfish, soybeans, insects, animal hair, dandruff of animal, etc. Included and many are proteins. At present, there are no medications that are effective against allergic symptoms, so it is important to keep allergens away from allergic humans in order to prevent allergic symptoms from occurring. However, many allergens exist in the natural world, and sometimes accompany those essential to human life, making it extremely difficult to remove them completely from their living spheres, making them virtually impossible. It is possible.
- JP-A-2000-5531 discloses an anti-allergen filter. Tea polyphenol, a tea extract component, is impregnated with a filter as an allergic deactivator.
- Japanese Patent Application Laid-Open Publication No. 2001-214134 discloses that cotton, hemp, wool, silk, rayon, nylon, polyester, and cotton containing a zirconium salt that inactivates by reacting with an allergen.
- Anti-allergen fibers such as ril and textile products such as bedding, masks and curtains are shown.
- an anti-mite agent As a means of controlling ticks on textile products, treatment with acaricides is known.
- a small amount of an anti-mite agent can only be expected to have a repellent effect, and it must be used in large amounts to kill mites, and its use in humans is limited in terms of safety.
- the anti-mite agent does not have any inhibitory effect on allergic symptoms caused by dust-derived allergens such as dead mites and excreta.
- Waterfowl feather products are widely used as bedding and clothing materials because of their excellent heat retention, moisture retention and breathability. In feather products, feathers, which are animal proteins, are food for ducks, and they absorb water due to human sweat, etc., and are appropriately warmed at the human body temperature. Therefore, the amount of allergens derived from mites tends to increase significantly.
- anti-allergen feather that has not been treated with an acaricide, is safe, and has the effect of adsorbing tick-derived allergens.
- JP-A-56-63355 and JP-A-61-258806 disclose deodorants containing metal phthalocyanine as an active ingredient.
- Japanese Patent Application Laid-Open No. 61-258886 describes that a derivative of metal phthalocyanine acts as an oxidation-reduction catalyst and exhibits an effect as a deodorant. Disclosure of the invention
- the inventor of the present invention has passed the enzyme-like catalysis of metal They have found that proteins can be denatured by their adsorptive properties and redox catalyst function.
- the present invention provides a decomposer for the generated allergen by utilizing such properties of metal phthalocyanine,
- the primary objective is to provide a method for decomposing allergens using an agent.
- the present invention provides an anti-allergen feather having an effect of adsorbing allergens derived from mites, such as mites, dead bodies and excreta, without using an anti-dust agent, a composition containing the anti-allergen feather, and a feather product. The purpose of.
- the allergen decomposer of the present invention made to achieve the first object is represented by the following formula (I)
- M is Fe, Co, Mn, Ti, V, Ni, Cu, Zn,
- the derivative of the metal phthalocyanine may or may not have the skeleton of the formula (I) substituted with a substituent.
- the allergen decomposer is a derivative of the metal phthalocyanine represented by the following formula:
- M is the formula (I) in the same; R nl, R n 2, R 3 and R 4 n 4 is R 1 R 2, R and R 4 are the same or different, CO OH
- the group is at least any substituent of the SO 3 H group, n 1, n 2, n 3 and n 4 are the same or different, 0 to 4, and l ⁇ n 1 + ⁇ 2 + is the number of the substituents satisfying ⁇ 3 + ⁇ 4 ⁇ 8.) or a salt thereof.
- the allergen decomposer includes a metal phthalocyanine derivative, metal phthalocyanine dicarboxylic acid, metal phthalocyanine tetracarboxylic acid, metal phthalocyanine octacarboxylic acid, metal phthalocyanine disulfonate, metal phthalocyanine tetrasulfonic acid, metal phthalocyanine. Octasulfonic acid or salts of these acids.
- the structural formula of metal phthalocyanine tetrasulfonic acid is represented by the following formula (VII)
- the structural formula of metal phthalocyanine otatasulfonic acid is represented by the following formula (VIII) Is exemplified.
- the allergen degrading agent is characterized in that the allergen is a protein-derived allergen.
- the allergen decomposer is characterized in that the metal phthalocyanine derivative is carried or mixed on a carrier.
- the method for decomposing an allergen to achieve the first object is characterized in that an allergen decomposer containing the metal phthalocyanine derivative as an active ingredient is placed in a living environment.
- Metal phthalocyanine which is an active ingredient of the allergen decomposer of the present invention Derivatives coordinate an allergen protein to its central metal, and cut peptide bonds by oxygen oxidation in the air, thereby reducing the molecular weight or changing the molecular structure. Derivatives of metal phthalocyanines not only simply adsorb allergens but also act as decomposition catalysts, so their action is permanent. The allergen enters the human body and, depending on its molecular structure, specifically binds to the antibody possessed by the human and causes allergic symptoms, but the allergen is reduced in molecular weight or the molecular structure of the allergen changes. If it does, it will not bind to the antibody that was reacting before.
- allergens in the living environment are largely degraded by this degrading agent, and even if a small amount enters the human body with an allergic constitution, the concentration does not reach the threshold for developing allergic symptoms. Therefore, if the allergen-decomposing agent of the present invention is placed in a living environment, even a human having an allergic substance can live daily life without developing symptoms.
- the antiallergen feather of the present invention made to achieve the second object is characterized in that the above-mentioned metal phthalocyanine derivative is carried on feathers.
- Derivative conductor metal phthalocyanine represented by the above formula used therefor (II), wherein, RR 2, R and R, but is S 0 3 H group, nl, n 2, n 3 and n 4 is , 1 is preferred. Also in the formula, it is preferred that M is Co or Fe.
- the anti-allergen feather is characterized in that the metal phthalocyanine derivative is a sodium salt or a copper (II) salt of the compound represented by the formula (II).
- the anti-allergen feather is characterized in that the amount of the metal phthalocyanine derivative carried is 0.1% by mass or more and 10% by mass or less based on the weight of the feather.
- the composition of the present invention is characterized by containing the above-mentioned anti-allergen feather.
- the feather product of the present invention is characterized by containing the above-mentioned anti-allergen feather.
- This anti-allergen feather, the composition and feather product containing it have not been treated with an anti-dandruff agent, and are not only mites themselves, but also mites allergens such as dead mites and excrement. Has the effect of adsorbing. Therefore, it is possible to remove allergens from mites.
- FIG. 1 is a photograph of a two-dimensional electrophoretic gel of the test solution of Experimental Preparation Example 1 and Comparative Preparation Example 1.
- FIG. 2 is a photograph of a two-dimensional electrophoretic gel of the test solution of Experimental Preparation Example 2 and Comparative Preparation Example 2.
- FIG. 3 is a photograph of a two-dimensional electrophoretic gel of the test solution of Experimental Preparation Example 3 and Comparative Preparation Example 3.
- FIG. 4 is a photograph of a two-dimensional electrophoretic gel of the test solution of Experimental Preparation Example 4 and Comparative Preparation Example 4.
- the allergen decomposer of the present invention contains a derivative of a metal phthalocyanine represented by the formula (I) as an active ingredient, and M is selected from the above-mentioned metals.
- M is selected from the above-mentioned metals.
- Fe, Co and Cu are particularly preferred.
- Most preferred is iron phthalocyanine tetracarboxylic acid.
- the metal phthalocyanine compound represented by the chemical formula (II) or a salt thereof may be a commercially available product or a compound produced by a known method. For example, it can be produced by the method described in “Phthalocyanine-Chemistry and Function-1” (written by Hiroyoshi Shirai and Nagao Kobayashi, IPC Publishing Co., Ltd., published February 28, 1997).
- iron phthalocyanine tetracarboxylic acid can be obtained as follows. To nitrobenzene, trimellitic anhydride, urea, ammonium molybdate, and ferric chloride anhydride are added, stirred, and heated to reflux to obtain a precipitate.
- the obtained precipitate is obtained by adding alkali and hydrolyzing it, and then adding an acid to make it acidic.
- Cobalt phthalocyanine otacarponic acid is replaced with pyromellitic anhydride and ferric chloride anhydride in place of trimellitic anhydride, which is the raw material of the iron phthalocyanine tetracarboxylic acid.
- the metal phthalocyanine derivative is supported or mixed with an organic or inorganic carrier to form an allergen decomposer.
- Fiber is particularly preferred as the organic carrier. Since the fibers are bulky and have a large surface area, the metal phthalocyanine or its derivative efficiently contacts the allergen in the air.
- Fiber materials include, for example, cellulosic fibers (cotton, hemp, rayon, etc.), protein fibers (wool, silk, etc.), polyamide fibers, polyester fibers, polyataryl fibers, poval fibers, polychlorinated vinyl fibers. All natural fibers, such as polyvinylidene chloride fiber, polyolefin fiber, and urethane fiber, regenerated fiber, semi-synthetic fiber, and synthetic fiber are used. Among them, cellulosic fibers, especially cotton, have good water absorption, It has good conditions for expressing enzyme-like functions as a medium that has absorbed water.
- Fibers carrying an allergen decomposer break down allergens while isolating allergen-integrated human bodies as clothing and futons from allergens, and decompose as curtains while blocking allergens that enter from outside. It decomposes allergens that are suspended or fallen as a carpet, and decomposes allergens that pass through as an air filter.
- the allergen decomposer and the method for decomposing allergens of the present invention will now be described more specifically with reference to Example 1.
- the mite antigen Derf II (manufactured by Asahi Breweries, Ltd.) was selected as the allergen, and electrophoresis when this mite allergen was mixed with iron phthalocyanine cyaninetetracarboxylic acid was compared with electrophoresis using only the allergen.
- Strips Prepare two types of one-dimensional electrophoresis gel films (hereinafter referred to as Strips), Stripp H4-7 and Stripp H3-10.5, and soak in each test solution to prevent drying. An appropriate amount of oil was added and allowed to stand for 10 hours. Each Strip was removed from the test solution, washed with water, set in a one-dimensional electrophoresis apparatus, added with silicone oil to prevent drying, and subjected to one-dimensional electrophoresis for 16 hours.
- Strips one-dimensional electrophoresis gel films
- Table 1 shows the one-dimensional electrophoresis program for StripHP 4 to 7.
- Table 2 shows the one-dimensional electrophoresis program for Stripp H 3 to 10.5.
- the Strip that had been subjected to one-dimensional electrophoresis was removed from the electrophoresis apparatus and washed with water.
- SDS sodium dodecy 1 sulfate (sodium dodecyl sulfate) equilibration buffer (1.5 mol ZL pH 8.8 Tris-C150 mmol / L, Urea 6 mol / L, 8 7 v / v% Glycerol 30 v / v%, SDS 2 v / v%, Bromophenolblue appropriate amount, distilled water) and DTT (dithiothreitol: 100 mg / l 0 mL)
- the Strip was immersed in 10 mL of the resulting solution and allowed to permeate for 10 minutes.
- the Strip was taken out, immersed in 10 mL of a solution obtained by adding iodoacetamide (250 mg / 10 mL) to an SDS equilibration buffer, and allowed to permeate for 10 minutes.
- the Strip was taken out, washed with water and wiped off, and then attached to a two-dimensional electrophoresis apparatus set with a two-dimensional electrophoresis gel, filter paper, an electrode gel, and a molecular weight marker, and subjected to electrophoresis for 1 hour and 40 minutes.
- Table 3 shows the two-dimensional electrophoresis program.
- the two-dimensional electrophoresis gel was placed in a developing solution (6.25 g of sodium carbonate, 37 wZv% honolemuanolaldehyde 0.05 mL, and made up to 25 OmL with distilled water). Soak and soak for 2-5 minutes. Stop solution (EDTA- N a 2 ⁇ 2 H 2 O 3. 6 5 g, filled up to 2 5 0 mL distilled water) was immersed two-dimensional electrophoresis gels impregnated for 10 minutes. Washing in which the two-dimensional electrophoresis gel was immersed in 250 mL of distilled water and allowed to permeate for 5 minutes was repeated three times. The silver-stained two-dimensional electrophoresis gel was photographed with a Pintgraph-1 electrophoresis photographing device manufactured by ATTO.
- the center row of spots is a molecular weight marker, which is a guide for molecular weight.
- the spots with the highest molecular weight in the photographs of Fig. 1, Fig. 2 and Fig. 3 are 14.4, 20.1, 30, 45, 6 in order from the bottom. 6, 97
- the spots of the molecular weight markers in the photograph of FIG. 4 are 3.5, 6.5, 14.3, 20.1, 30 and 45 KDa in order from the bottom.
- the horizontal axes of A and B, which are divided by the spot row at the center of each photograph, represent the Stripp H of one-dimensional electrophoresis.
- the spot in A of each photograph is a mixture of iron phthalocyanine tetracarboxylic acid rim and mite allergen, and the spot in B is only mite allergen. If there is no change in mite allergens due to the iron lip mouth cyanine tetracarboxylic acid rim, the spots in A and B are similar, but the spots in A near pH 5-6 disappear from the photo. It can be seen that the mite allergen is changed by the iron lid mouth cyanine tetracarboxylate.
- a dough containing 1% by weight of iron cap mouth cyanine tracarboxylic acid was used as a sample of functional fibers for allergen degradation.
- Macroscopic evaluation was performed before administration and 1, 24, 48, and 72 hours after removal of the test substance. Judgment was made on erythema (formation of crusts) and floating species, respectively, in accordance with the criteria of Draise (Appendix3). The mean value and standard deviation were calculated for erythema (scab formation), floating species, and their total score (T S) at each observation time point for normal skin and damaged skin. In addition, according to the evaluation criteria of IS 01 0993-10 (Appendix 3), the primary irritation index (erythema (crust) was evaluated for normal skin and damaged skin at 24, 48 and 72 hours, respectively.
- the PII was 0.0 for both normal and damaged skin, and its irritation strength was determined to be "Negligile", indicating that there is no problem with the safety of the functional fiber on the skin.
- the same allergen-degrading functional fiber was used as a sample, and was similarly used as damaged skin of a egret.
- Functional fibers moistened with water for injection were applied to each area of normal skin and damaged skin, covered with gauze, and fixed with taping tape. Gauze and taping tape were applied in the same manner at each of the other sites. Furthermore, it was covered and fixed using a cloth cover and a tube-type net bandage. After 23 hours, the functional fibers, gauze and taping tape were removed, and the administration site was wiped with mild hot water. The administration period was 21 days, and the irritation was visually evaluated one hour after the daily removal. Judgment was performed for erythema (scab formation) and floating species in accordance with the Draize criteria. It was.
- the average value and standard deviation of erythema (scab formation), floating species, and their total score (TS) were calculated at each observation point for normal skin and damaged skin.
- the animals were exsanguinated and killed under pentobarbital sodium anesthesia, and the skin at each administration site was fixed with a 10% neutral buffered formalin solution, followed by HE staining and histopathological examination.
- the inside of the conjunctival sac was washed with 230 to 330 mL of warm water to remove the test substance.
- the left eye was untreated in both the unwashed group and the washed group. At 1, 24, 48 and 72 hours after administration, the cornea, iris and conjunctiva were observed in comparison with untreated control eyes.
- a clear irritative reaction was expressed in all cases, and corneal opacity and surface roughening, iris depressed blood, conjunctival redness, floating species, secretions, etc. were observed.
- coloring of the cornea and iris (green) due to the test substance was observed. These responses were most pronounced 24 hours after administration. Thereafter, it gradually recovered, and the reaction between the cornea and the iris disappeared by 72 hours after administration, and the reaction of the conjunctiva disappeared by day 10. In addition, only iris coloring was continuously observed until day 21 after administration.
- the evaluation of ocular mucosal irritation was Modera telyyiriritatatng.
- the functional fiber which is the test substance, is immersed in 0.2 mL of a physiological saline solution prepared in mL at a ratio of 0.2 mL Z 1 mL and extracted in an autoclave with 1 2 1 2 for 1 hour. It was cooled to 0 ° C, stored at room temperature, and used within 24 hours.
- the physiological fiber extract of functional fiber is extremely low in toxicity.
- the toxicologically toxic amount under the test conditions in this study was 20 mL / kg for both males and females (the functional It was presumed to exceed 4 gZkg in fiber equivalent.
- CD (SD) IGS (SPF) rats each of 26 males and 26 females, were pre-quarantine-bred for 1 week, and no abnormalities were observed. Based on the body weight measured before preliminary breeding, the animals were assigned to each group by the stratified randomization method. Surplus animals that were not assigned to groups were grouped. At the time of administration, the males and females were 6 weeks old and weighed 178 to 197 g for males and 122 to 142 g for females.
- the functional fiber which is the test substance, is immersed in the prepared artificial saliva at a rate of 0.2 g / 1 mL, and the soil is placed in an autoclave. Extracted with 2 for 1 hour. Thereafter, the mixture was cooled to 20 to 30 ° C, stored at room temperature, and administered within 24 hours.
- the dose was 50 niL of the extract of the body weight of 1 kg based on the body weight immediately before the administration. 50 mL of the extract corresponds to 10 g in terms of the extracted fiber. The number of administrations was one. After fasting for at least 18 hours from the evening before the administration, the mice were orally administered by gavage using a disposable syringe and an oral sonde between 9:00 and 13:30. The observation period was 14 days after administration.
- the lethal dose was estimated to be 10 g Zkg or more in terms of functional fibers.
- CD (SD) IGS (SPF) rats each of 26 males and 26 females, were quarantined for one week, and no abnormalities were observed.
- the body weight was measured immediately before quarantine breeding and assigned to each group by the stratified randomization method.
- Surplus animals not assigned to groups were removed from the study on the day of grouping, euthanized and disposed of.
- the age at the time of administration is He was 6 weeks old and weighed 172-186 g for males and 130-151 g for females.
- the required amount of the test substance, iron phthalocyanine cyaninetetracarboxylic acid was weighed and dissolved in purified water whose pH was adjusted to 10.2 with 1N sodium hydroxide. After dissolution, adjust the pH to 7.11 using 1N hydrochloric acid, and then administer the solution with purified water so that the final concentration of iron phthalocyanine cyanine tetracarboxylic acid becomes 100 mg ZmL. A liquid was prepared. Based on the Pharmaceutical Toxicity Test Guidelines, the maximum dose that can be administered technically was set at the upper limit of 2000 mg / kg for oral administration, which was set as the test substance administration dose.
- a control group to which a control substance (purified water of the Japanese Pharmacopoeia) was administered was set, and the test group was divided into two groups. Each group was assigned 10 males and 10 females.
- the volume of the administered liquid was 20 mLZkg, and was individually calculated based on the body weight immediately before administration on the day of administration. The number of administrations was one.
- gavage was administered using a disposable syringe (TERMO Co., Ltd.) and an oral sonde (Fuchigami Instrument Store, disposable oral sonde) for 14 days. Observed. The general condition and the observation of life and death were continuously observed before administration and 5, 15, 30 minutes, 1, 2, and 4 hours after administration.
- Approximate lethal dose was calculated from the mortality rate during the observation period based on the mortality rate, and the approximate minimum lethal dose of iron phthalocyanine tetracarboxylic acid under this test condition was estimated to be 2000 mg / kg or more. .
- a 5-week-old male Crj; Hart1ey guinea pig was divided into a vehicle control group and a test substance sensitized group, and the skin sensitization of functional fibers was tested by the MaXimization method. After adding 10 volumes of methanol to the minced functional fiber as a test substance and extracting at room temperature, the methanol was distilled off and extraction of the functional fiber from 15.1.88 g to 5.48 2 g Thing was obtained.
- dimethyl sulfoxide a vehicle control
- dimethyl sulfoxide a vehicle control
- the functional fiber methanol extract was sensitized at a concentration of 10%, and then induced with the 10%, 1%, and 0.1% functional fiber methanol extracts and the vehicle control. .
- skin reactions were occasionally observed at the site where the 10% methanol extract was induced, and the average evaluation point and positive rate at the site where the 10% methanol extract was induced were 0.7 and 10% at 24 hours after induction and 1. at 48 hours. 4 and 40%.
- Erythema at evaluation point 1 was scattered at the site where the 1% functional fiber methanol extract was induced, but no positive cases were found. No skin reaction was observed in the 0.1% functional fiber methanol extract and the vehicle control induced site. Extraction of functional fiber methanol from the positive rate at 48 hours after induction The substance was evaluated as having a moderate (Grade III) skin sensitization by challenge at a concentration of 10%.
- DNC B 2,4-dinitrochlorobenzene
- the positive rate at 48 hours is 100%, and the DNCB is severe (Gr ade
- each sensitizer was administered intradermally in combination with an adjuvant, and 7 days later, each sensitized substance was occluded for 48 hours for transdermal sensitization. On day 21 after the intradermal administration, each substance was occluded and applied to the skin for 24 hours, and the skin reaction was evaluated 24 and 48 hours after removal. Criteria for skin reaction were as follows: erythema and crust: no erythema 0, slight erythema 1, obvious erythema 2, moderate erythema 3, crust with strong erythema 4, Regarding floating species, there are 0 floating species, 1 slight floating species, 2 medium floating species, and 3 strong floating species.
- the functional fiber methanol extract was considered to have skin sensitization to guinea pigs, and the lowest evoked concentration was considered to be 10%. Also,
- the methanol extract of the functional fiber used in the skin sensitization test of 7 was subjected to skin photosensitization by the Adjuvantand Strip method using a 5-week-old male Crj: H art 1 ey guinea pig. did. 0.1 mL of each substance to be administered was applied to the back of the guinea pig after hair removal, and 30 minutes later, ultraviolet rays of about 10.2 Joule S / cm 2 were irradiated. The same treatment was performed for 5 consecutive days and photosensitization was performed. On the 17th day after the final sensitization, 0.1 mL of each substance was applied symmetrically to the depilated back skin and left open. The portion was covered with aluminum foil and irradiated with ultraviolet rays of about 10 ⁇ 2 Jou 1 es / cm 2 to induce photo-initiation. The skin reaction was determined 24 hours and 48 hours after light induction.
- sensitization was performed by dissolving a methanol extract of the functional fiber in dimethyl sulfoxide at a concentration of 10%, and elicited at a concentration of 1%. As a result, erythema with a score of 1 was scattered, but no positive cases were found, and all cases were judged to be negative.
- the vehicle control group was sensitized and induced with dimethyl sulfoxide. As a result, no skin reaction was observed at any of the induced sites.
- 6-methylcoumarin (6-MC) was sensitized at a concentration of 5% and induced at a concentration of 1%. As a result, erythema with a score of 2 to 4 was observed in the UV-irradiated area of the 6-MC-inducing site, and all cases were determined to be positive.
- the methanol extract of the functional fiber had no skin photosensitization to guinea pigs.
- the methanol extract of the functional fiber used in the skin sensitization test of 7 was subjected to a phototoxicity test on 5-week-old male Crj: Ht1ey guinea pigs by the method of Morikawa et al.
- a methanol extract of the functional fiber dissolved in dimethylsulfoxide at a concentration of 10% was used.
- dimethylsulfoxide was used.
- 0.05% 8—methoxypsoralen was applied to the back of the guinea pig from which the hair had been removed, in an amount of 0.03 mL.
- ultraviolet rays of about 11.2 Joules Z cm 2 were irradiated. Skin reactions were determined 24 and 48 hours after irradiation.
- the functional fiber methanol extract had no phototoxicity to guinea pigs.
- methanol of functional fiber The extract was searched for the mutagenic ability.
- the methanol extract is a residue obtained by adding 10 times the amount of methanol to the minced functional fiber, extracting the mixture by stirring at room temperature for 24 hours, and distilling off the methanol with a rotary evaporator.
- the number of revertant colonies treated with this test substance was more than twice as high as that of the negative control in both base pair substitution type and frame shift type strains regardless of whether metabolic activation was present or not. There was no increase and no dose response was observed. Therefore, it is judged that the methanol extract of the functional fiber has no mutagenic ability under the test conditions.
- the presence or absence of clastogenicity in the methanol extract of the functional fiber was searched.
- the test was performed using DMS O as a medium.
- the maximum test dose of the test substance in the cytostatic test was 5.0 mg / mL.
- the 50% cell growth inhibition concentration was 5.
- OmgZmL or more in the absence of a short-time treatment metabolic activation system hereinafter abbreviated as "S9 mix method”
- + S9 mix method in the presence of the metabolic activation system for short-time treatment (hereinafter abbreviated as + S9 mix method)
- it was 0.840 mg Zml.
- the test substance precipitates in 0.3 0.33 mg gZ It was found at more than mL.
- test dose for the chromosome aberration test was set at 3 mg / mL, with the highest test dose for the S9mix method being 0.313 mg / mL, and diluted at a common ratio of 2 to 3 doses.
- the maximum test dose for the + S9mix method was 1.25 mgZmL, and four doses diluted at a common ratio of 2 were set.
- the frequency of appearance of cells having a chromosomal structural abnormality and polyploid cells in the S9mix method was 5% or less at any of the test doses.
- the + S9mIX method showed a dose-dependent increase in the frequency of cells with chromosomal structural abnormalities above 0.313 mg / mL, and was positive.
- it was determined to be positive it was determined to be positive, so the continuous treatment method was not implemented.
- the frequency of appearance of cells with chromosomal structural abnormalities showed an appropriate value, indicating that the test was properly performed. Based on the above results, it was determined that the test substance had clastogenicity to fibroblasts (CHLZ IU cells) derived from Chinese 'hamster lung.
- the cell growth inhibition test is as follows. Short treatment Part 1; over s 9 mix method, seeded with a diameter of 6 0 mm plastic Petri dish one per 2 X 1 0 4 cells (culture 5. 0 m L), and cultured for 3 days .
- the highest test dose of the test substance is 5.O mg / mL, and a total of 10 doses (0.010, 0.020, 0.039, 0. 0 78, 0.156, 0.313, 0.625, 1.25, 2.5 and 5. O mg / mL).
- a vehicle (DMSO) control group was provided as a negative control.
- the medium or the test solution for each test dose was added at 50 ⁇ to one petri dish per dose, and allowed to act at 37 ° C for 6 hours.
- the culture medium of the petri dish was removed, the cells were washed with physiological saline, and 5 mL of a new culture medium was added. The culture was continued for another 18 hours. After the culture, remove the culture solution of the petri dish, After washing the cell surface with physiological saline, the cells were fixed with a 10% formalin solution. After fixing, the cells were stained with a 0.1% crystal violet solution. The cell proliferation rate was measured from the density of the cell staining using a monolayer culture cell densitometer (Monocerator, Olympus Optical Co., Ltd.). At this time, the value of the vehicle control cells was 100%. From this, the 50% cell growth inhibitory concentration (approximate value) of the test substance was determined.
- the chromosome aberration test is as follows.
- the test dose of the test substance was determined by performing a cell growth inhibition test.
- the concentration of 50% cell growth inhibition was 5.
- the value was 0.840 mgZmL.
- the test dose for the short-term treatment method in the chromosome aberration test was as follows.
- the maximum test dose of the test substance was 0.313 mg ZmL, and a total of three doses diluted by a common ratio of 2 from the maximum test dose were set.
- Untreated and vehicle control groups were provided as negative controls, and mitomas were used as positive controls.
- a group treated with isin C (0.05 ⁇ g / mL) was provided.
- corsemide (GIB COZLot No. 11 25 54 46) was added to a final concentration of 0.2 ⁇ g two hours before sample preparation. Zm L was added. Two hours later, the culture solution of each petri dish was transferred to a Spitz tube. Immediately, 2 mL of a 0.25% trypsin solution was added to each dish, and after detaching the cells, the cells were collected in the above-mentioned Spitz tube and centrifuged (10000 rpm, 5 minutes).
- the petri dish for cell growth rate was fixed and stained in the same manner as in the cell growth inhibition test described above, and then the cell growth rate was measured. Under a microscope, 200 well-expanded metaphase images per treatment group (100 per petri dish) were observed, and the types of structural abnormalities and the number of cells having abnormalities were recorded. At the same time, the number of ploidy cells was also recorded (37 or more chromosomes including 3 media were recorded as ploidy). In order to conduct objective observations, observations were made by blind method.
- a gap means that the unstained part is on the vertical axis of the stained part, the width of which is less than the width of the chromatid and the shape of the unstained part is clear, and cutting means that the unstained part is the vertical part of the chromatid. If on the axis, the width is greater than the width of the chromatid and the shape of the unstained part is clear, or a fragment exists off the axis of the chromosome or chromatid.
- Mutual exchange by cutting two or more places in the split field And other structural anomalies as other.
- Chromatid exchange eg, four radial exchange, cte
- Chromosome type exchange (dicentric, circular, etc.)
- the frequency of cells with chromosomal structural abnormalities and polyploid cells in the S9 mix method was less than 5% at any of the test doses .
- the frequency of chromosomal ploidy cells was 5% or less at all test doses, but the frequency of cells with chromosomal structural abnormalities was 0.33.
- 0.625 and 1.25 mg / mL showed dose-dependent increases of 15.5, 49.5 and 73.0%, respectively. Precipitation of the test substance was observed at 0.313 mg / mL or more.
- Cell culture was performed using a carbon dioxide incubator at a temperature of 37.0 ⁇ 1.0 ° C (actual temperature: 36.9 to 37.4 ° C), and a CO 2 concentration of 5.0 ⁇ 0.5. % (Actually measured concentration: 4.8 to 5.1%), and cultured statically under humidified conditions.
- the subculture operation was performed with the cell density being about 30 to 70% of the flask bottom area.
- the medium in the flask was removed and lightly rinsed with Dulbecco's phosphate buffer without Ca2 + and Mg2 + . After aspirating and removing the PBS (-), a small amount of 0.05% trypsin and 0.02% EDT A ⁇ 2Na (Dotin Kagaku Co., Ltd., Lot No.
- PBS (-) trypsin ZE DTA solution
- the medium was added to collect the cells, transferred to a centrifuge tube, and centrifuged at about 80 rpm for 2 minutes. The supernatant was removed, and a new medium was added to loosen the cells to obtain a cell suspension.
- the cells were diluted with a medium so as to have a cell density of 1/3 to 110 before the passage and seeded in a new flask.
- PBS PBS
- Washed with ell After adding 3 mL of methanol to each ⁇ ; nil and leaving it to stand for 10 minutes to fix the cells, remove the methanol and add 3 mL of 5% Giemsa solution diluted with phosphate buffer (pH 6.4). In addition, the mixture was left still for 10 minutes to stain the colonies. Each well was washed once with purified water, dried, and the number of colonies determined to consist of 50 or more cells was counted with the naked eye or a stereoscopic microscope.
- the control group had a colony forming ability of 95%, indicating good colony forming ability. No statistically significant difference was found in the number of colonies in the control group and the wells with 100% extract added to the negative material.
- IC 5 Q values of the standard material A ⁇ Pi standard material B are each 1.3 2% and 6 8.9 2%, both met the established criteria for the test.
- the high-concentration extract (70% or more) showed a tendency for the colonies to become smaller, indicating that the cell growth ability Some effects were suggested. However, there was no difference in the number of colonies formed in the functional fiber extract from the control group, and the IC 5 of the functional fiber extract was 5 . The value is greater than 100%, There was no effect on the knee formation ability.
- the present invention is an anti-allergen feather carrying a metal phthalocyanine compound represented by the formula (II) (hereinafter referred to as a metal phthalocyanine compound (II)) or a salt thereof as a derivative of the metal phthalocyanine.
- the amount of the metal phthalocyanine compound (II) or a salt thereof supported on the feather is preferably 0.1% by mass or more and 10% by mass or less, more preferably 0.3% by mass, based on the feather weight. It is at least 5% by mass and more preferably at least 0.5% by mass and at most 3% by mass.
- metal carrier data port Shianin compound (II) or 0.1 wt% or more 1 0 mass 0/0 more than the amount of a salt thereof, is excellent in the effect of adsorbing da E derived allergen anti Arerugen feathers .
- Examples of the material of the anti-allergen feathers include feathers collected from ducks, goose, crows, mallards, ducks, Chinese duck, pekin duck, dozen (vinoreg rim.
- As the material of the anti-allergen feathers it is possible to use Fuza I (large feathers, feathers having feathers at wing portions), down (chest hair, fluff), small feathers (feathers), and the like.
- Examples of the salt of the metal phthalocyanine compound (II) include a salt with an inorganic base and a salt with an organic base.
- Preferred examples of the salt with an inorganic base include alkaline metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt; and copper ( II) Salts, ammonium salts and the like.
- Suitable examples of salts with organic bases Examples thereof include salts with trimethylamine, triethylamine, pyridine, picolin, ethanolamine, diethanolamine, triethanolamine, dihexamine, and hexylamine.
- M is preferably Co or Fe in the above formula (II).
- Such metal phthalocyanine compounds are preferably Co or Fe in the above formula (II).
- the salt of the metal phthalocyanine compound (II) is a sodium salt or a copper (II) salt.
- the anti-allergen feather can be produced, for example, by the following method.
- the feathers are pre-treated.
- the pre-treatment includes pre-dust removal to remove earth and sand and other impurities in raw material feathers, dust before washing to remove dust and feather dirt that cannot be removed by washing pebbles, sand, fatty acids, etc., water (normal temperature water, Washing with hot water).
- the pretreated feather is immersed in an aqueous solution of the metal phthalocyanine compound (II) or a salt thereof at a temperature of 80 ° C or more and 100 ° C or less for 30 minutes to 2 hours, and washed with water.
- an anti-allergen feather carrying the metal phthalocyanine compound (II) or a salt thereof can be produced.
- the content of the metal phthalocyanine compound (II) or a salt thereof in the aqueous solution is preferably 0.01% by mass or more and 10% by mass or less, more preferably 0.1% by mass or less, based on the weight of the feathers. 5 mass% or less is more preferable.
- the aqueous solution of the metal phthalocyanine compound (II) or a salt thereof may contain an acid commonly used in an acidic dyeing method such as formic acid, acetic acid, hydrochloric acid, phosphoric acid, and citric acid.
- the acid is used to cationize the amino group of the amino acid constituting the feather and to reduce the solubility of the metal phthalocyanine compound so that the feather is supported on the feather.
- the anti-allergen feather carrying the metal phthalocyanine compound (II) or a salt thereof may be further treated with a mordant, a fixative, or the like.
- a mordant include tannic acid, aluminum salt (for example, aluminum acetate, birch alum, roasted alum, etc.), chromic acid (for example, chromium acetate, chromium alum, etc.), and iron salt (for example, sulfamic acid.
- Ferric iron, iron acetate, ferrous chloride, ferrous sulfate, etc., tin salts (eg, soda stannate, stannous chloride, etc.), copper salts (eg, copper acetate, etc.), varnish Salt (for example, palladium chloride) can be used.
- Salts such as copper salts (eg, copper sulfate), aluminum salts, and quaternary ammonium salts can be used.
- the free SO 3 H group or COOH group in the metal phthalocyanine compound (II) can form a salt, and the metal phthalocyanine compound (II) or the salt is firmly supported on feathers. be able to. Therefore, even if the anti-allergen feather carrying the metal phthalocyanine compound (II) or a salt thereof is washed, it can be maintained for a long time.
- the present invention is a composition
- a composition comprising an anti-allergen feather carrying metal phthalocyanine compound (II) or a salt thereof.
- the composition may be processed into a shaped article such as a feather product in combination with other materials.
- the present invention is a feather product containing an anti-allergen feather carrying a metal phthalocyanine compound (II) or a salt thereof.
- the down product include bedding such as a down duvet and clothing such as a down jacket.
- the anti-allergen feathers of the present invention will be described more specifically with reference to Examples 2 and 3.
- the bulkiness was measured in a test room at a temperature of 20 ° C and a relative humidity of 65% in accordance with the JIS L1903 feather test method.
- the feathers were immersed in this reagent solution and left at 97 ° C. for 50 minutes. Most of cobalt phthalocyanine sodium polysulfonate is absorbed by feathers Exhausted.
- the adsorption force of the allergen was measured as follows.
- the feathers not treated with the reagent solution in Examples 2 and 3, ie, dozen feathers that had been subjected to the pre-dusting treatment, the dusting treatment before washing, and the washing treatment with water (down 85% by mass, small Feather 1 5 mass 0/0) were used.
- mite allergen antigen solution purified mite allergen rDer2 (trade name), manufactured by Asahi Breweries, Ltd.) (1 ⁇ g / mL) (200 ⁇ 1). 5 for 1 hour. After the sample was removed, the solution was centrifuged (1000 rpm, 3 minutes), and the supernatant (1001) was measured by the ELISA method.
- the supernatant was injected into a microplate (96 // rebrate, manufactured by Shii-Dani Bininore, manufactured by Dynatech) and maintained at 25 ° C. for 2 hours. Thereafter, the supernatant was removed from the wells using a micropipette. The wells were washed three times with a PBS solution.
- Biotin-labeled anti-mouse IgG (H + L) antibody solution (manufactured by VE CTOR, BIOT I NYLATED ANT I — MO USEI gG (H + L) (brand name)) (1 ⁇ g / mL) was injected into the above-mentioned microphone plate at 1 0 ⁇ l well, and maintained at 25 ° C for 2 hours. Thereafter, the antibody solution was removed from the wells using a micropip. The wells were washed once with 0.05% Tween_PBS solution.
- An avidin solution (manufactured by VE CTOR, AL KAL I NE PHO S PH ATA SE AV IDIND (trade name)) (100 units) was injected into the microplate at 100 ⁇ l in a well of 25 ° C. Maintained for 0.5 hours. Thereafter, the supernatant was removed from the wells using a micropipette. The wells were washed three times with 0.05% Tween ⁇ -PBS solution.
- VE-CTOR P—NITRO PHE NYLPHOS PHAT E (trade name)
- 500 ⁇ g / mL was injected into the microplate at 100 ⁇ l / ⁇ L. And maintained at 25 for 10 minutes. After that, a 5 ⁇ NaOH aqueous solution was injected into the 1001 Z well to stop the reaction.
- Adsorption rate (%) [(concentration of mite allergen after sample immersion: / ⁇ gZm l) / (concentration of mite allergen before sample immersion: 1 ⁇ gZm 1)] X 100 Table 5
- the anti-allergen feather carrying the metal phthalocyanine derivative of the present invention did not use an acaricide and had an excellent ability to adsorb mite allergens.
- the feather of the present invention does not use an anti-mite agent and has an excellent anti-allergen effect.
- the allergen-decomposing agent of the present invention has been experimentally confirmed to have a drug effect of decomposing the allergen by the action of a metal phthalocyanine derivative as an active ingredient, and its safety has also been experimentally confirmed. It can be used as
- the anti-allergen feather of the present invention has an effect of adsorbing allergen, it can be applied to a composition and a feather product containing the same.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Textile Engineering (AREA)
- Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Mechanical Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Catalysts (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04724172A EP1683847B1 (en) | 2003-11-12 | 2004-03-29 | Allergen decomposer and antiallergenic feather |
US10/579,059 US20080108593A1 (en) | 2003-11-12 | 2004-03-29 | Allergen Decomposer and Antiallergenic Feathers |
CN2004800332887A CN1878845B (zh) | 2003-11-12 | 2004-03-29 | 变应原分解剂和抗变应羽毛 |
AT04724172T ATE520756T1 (de) | 2003-11-12 | 2004-03-29 | Allergenzersetzer und antiallergene feder |
KR1020067009223A KR101137731B1 (ko) | 2003-11-12 | 2004-03-29 | 알레르겐 분해제 및 항 알레르겐 우모 |
JP2005515390A JP3858080B2 (ja) | 2003-11-12 | 2004-03-29 | アレルゲン分解剤、および抗アレルゲン羽毛 |
US12/453,878 US20090291934A1 (en) | 2003-11-12 | 2009-05-26 | Method for decomposing an allergen |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-382565 | 2003-11-12 | ||
JP2003382565 | 2003-11-12 | ||
JP2003387100 | 2003-11-17 | ||
JP2003-387100 | 2003-11-17 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/453,878 Continuation US20090291934A1 (en) | 2003-11-12 | 2009-05-26 | Method for decomposing an allergen |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005047414A1 true WO2005047414A1 (ja) | 2005-05-26 |
Family
ID=34593938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/004445 WO2005047414A1 (ja) | 2003-11-12 | 2004-03-29 | アレルゲン分解剤、および抗アレルゲン羽毛 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20080108593A1 (ja) |
EP (1) | EP1683847B1 (ja) |
JP (1) | JP3858080B2 (ja) |
KR (1) | KR101137731B1 (ja) |
CN (1) | CN1878845B (ja) |
AT (1) | ATE520756T1 (ja) |
WO (1) | WO2005047414A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007119952A (ja) * | 2005-10-28 | 2007-05-17 | Sojitz Corp | 加工羽毛の製造方法 |
JP2022552637A (ja) * | 2019-09-27 | 2022-12-19 | エムエムエフ アンド ティー デセンヴォルヴィミェント テクノロジコ イー イノヴァサオ リミターダ | 口腔衛生用の組成物および口腔衛生用の組成物の製造プロセス |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201001070D0 (en) | 2010-01-22 | 2010-03-10 | St George's Hospital Medical School | Theraputic compounds and their use |
JP5718348B2 (ja) * | 2010-10-01 | 2015-05-13 | 株式会社アイフォーレ | 化粧料組成物 |
CN103755713B (zh) * | 2014-01-27 | 2015-08-12 | 福州大学 | 一种八磺酸基酞菁及其制备方法和应用 |
US10617894B2 (en) * | 2016-04-05 | 2020-04-14 | Innonix Technologies, Incorporated | Compositions for reducing inhalation of toxic air pollution components |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5663355A (en) | 1979-10-31 | 1981-05-29 | Nippon Carbide Kogyo Kk | Deodorant |
JPS61258806A (ja) | 1985-05-11 | 1986-11-17 | Aasu Kuriin:Kk | 高分子物質を有効成分に含む消臭剤 |
JPH01111067A (ja) * | 1987-10-20 | 1989-04-27 | Shirai Hiroyoshi | 消臭繊維とその製造方法 |
JPH10273875A (ja) * | 1997-03-28 | 1998-10-13 | Kohjin Co Ltd | 抗菌防臭ならびに消臭性能を有する組成物 |
JP2001214367A (ja) * | 2000-02-02 | 2001-08-07 | Shinto Fine Co Ltd | 抗アレルゲン繊維及び繊維製品 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB810548A (en) * | 1955-03-31 | 1959-03-18 | Hoechst Ag | Process for fixing pigments on fibrous materials or foils |
JPS6468578A (en) * | 1987-09-02 | 1989-03-14 | Daiwa Spinning Co Ltd | Fiber having excellent washing fastness and deodorizing function |
JPH10117657A (ja) * | 1996-10-16 | 1998-05-12 | Masashi Fujii | ダニ類の誘引物質 |
CN1197626C (zh) * | 1999-04-30 | 2005-04-20 | 吴羽化学工业株式会社 | 除臭结构体及除臭剂 |
US6465446B1 (en) * | 2001-03-12 | 2002-10-15 | John C. Dykstra | Treatment of dermatitis by the topical application of Δ5-androstene-3β-ol-7,17 dione and metabolizable precursors thereof |
JP2003213548A (ja) * | 2002-01-18 | 2003-07-30 | Atsushi Komiyama | 治療補助具 |
US6811796B2 (en) * | 2002-04-22 | 2004-11-02 | Matsuura Yakugyo Co., Ltd. | Preventive or therapeutic agent for pollen allergy, allergic rhinitis, atopic dermatitis, asthma or urticaria, or health food for prevention or improvement or reduction of symptoms thereof |
-
2004
- 2004-03-29 US US10/579,059 patent/US20080108593A1/en not_active Abandoned
- 2004-03-29 AT AT04724172T patent/ATE520756T1/de not_active IP Right Cessation
- 2004-03-29 CN CN2004800332887A patent/CN1878845B/zh not_active Expired - Lifetime
- 2004-03-29 JP JP2005515390A patent/JP3858080B2/ja not_active Expired - Lifetime
- 2004-03-29 KR KR1020067009223A patent/KR101137731B1/ko active IP Right Grant
- 2004-03-29 EP EP04724172A patent/EP1683847B1/en not_active Expired - Lifetime
- 2004-03-29 WO PCT/JP2004/004445 patent/WO2005047414A1/ja active Application Filing
-
2009
- 2009-05-26 US US12/453,878 patent/US20090291934A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5663355A (en) | 1979-10-31 | 1981-05-29 | Nippon Carbide Kogyo Kk | Deodorant |
JPS61258806A (ja) | 1985-05-11 | 1986-11-17 | Aasu Kuriin:Kk | 高分子物質を有効成分に含む消臭剤 |
JPH01111067A (ja) * | 1987-10-20 | 1989-04-27 | Shirai Hiroyoshi | 消臭繊維とその製造方法 |
JPH10273875A (ja) * | 1997-03-28 | 1998-10-13 | Kohjin Co Ltd | 抗菌防臭ならびに消臭性能を有する組成物 |
JP2001214367A (ja) * | 2000-02-02 | 2001-08-07 | Shinto Fine Co Ltd | 抗アレルゲン繊維及び繊維製品 |
Non-Patent Citations (1)
Title |
---|
HIROFUSA SHIRAI; NAGAO KOBAYASHI: "phthalocyanine -chemistry and function", 28 February 1997, INDUSTRIAL PUBLISHING & CONSULTING, INC. |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007119952A (ja) * | 2005-10-28 | 2007-05-17 | Sojitz Corp | 加工羽毛の製造方法 |
JP4732123B2 (ja) * | 2005-10-28 | 2011-07-27 | ヤマセイ株式会社 | 加工羽毛の製造方法 |
JP2022552637A (ja) * | 2019-09-27 | 2022-12-19 | エムエムエフ アンド ティー デセンヴォルヴィミェント テクノロジコ イー イノヴァサオ リミターダ | 口腔衛生用の組成物および口腔衛生用の組成物の製造プロセス |
Also Published As
Publication number | Publication date |
---|---|
JP3858080B2 (ja) | 2006-12-13 |
CN1878845B (zh) | 2011-02-02 |
KR20060112658A (ko) | 2006-11-01 |
CN1878845A (zh) | 2006-12-13 |
US20080108593A1 (en) | 2008-05-08 |
EP1683847A1 (en) | 2006-07-26 |
JPWO2005047414A1 (ja) | 2007-08-23 |
EP1683847A4 (en) | 2007-11-07 |
ATE520756T1 (de) | 2011-09-15 |
EP1683847B1 (en) | 2011-08-17 |
KR101137731B1 (ko) | 2013-11-28 |
US20090291934A1 (en) | 2009-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2698182C1 (ru) | Антимикробные композиции на полимерной основе и способ их применения | |
Asharani et al. | Toxicity of silver nanoparticles in zebrafish models | |
KR101670953B1 (ko) | 살균 탈취제 제조방법 및 이에 의해 제조된 살균 탈취제 | |
CN107938338A (zh) | 一种纺织防霉抗菌剂及其制备和使用方法 | |
CN105407729A (zh) | 包含聚胺的组合物和方法 | |
US20090291934A1 (en) | Method for decomposing an allergen | |
CN111557938A (zh) | 一种快速损伤病毒囊膜的消毒制剂 | |
Cullen | Normal ocular features, conjunctival microflora and intraocular pressure in the Canadian beaver (Castor canadensis) | |
Sahu et al. | Photochemical toxicity of drugs intended for ocular use | |
EP2081428A2 (en) | Antipediculosis composition having a lice-suffocating activity | |
JP5735276B2 (ja) | 鳥類の羽毛及び魚類のうろこの混合物を有効成分として含有する細胞増殖性疾病の予防及び治療用薬学的組成物 | |
Sosedova et al. | Synthesis of chalcogen-containing nanocomposites of selenium and tellurium with arabinogalactan and a study of their toxic and antimicrobial properties | |
Werther et al. | Ocular histomorphometry of free-living common kestrels (Falco tinnunculus) | |
JP4048218B2 (ja) | アレルゲン分解機能を有する繊維製品 | |
JP3885096B2 (ja) | アレルゲン分解繊維素材 | |
Peckham | Case report: lens opacities in fowls possibly associated with epidemic tremors | |
US11596149B2 (en) | Methods of preparing highly charged polyethylenimine and compositions and uses thereof | |
CN108902127A (zh) | 一种鸟类剥制标本环保制作方法 | |
Shivaprasad et al. | Ophthalmology of Galloanserae: Fowl, Waterfowl, & Relatives | |
Maertins et al. | Electroretinographic assessment of early retinopathy in rats | |
Lakshmanan et al. | Therapeutic Management of Conjunctivitis: A Case Report in a Cockatiel and Aseel Bird | |
Kern | Environment in relation to allergic disease | |
EP0883808A1 (de) | Verfahren zur bestimmung der phototoxizität und/oder photosensibilität von stoffen oder stoffgemischen sowie dessen verwendung | |
KR101386233B1 (ko) | Ir 3535 유도체를 유효성분으로 포함하는 모기 기피용 조성물 | |
Sahu et al. | Fotokemijska toksičnost lijekova namijenjenih okularnoj uporabi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480033288.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005515390 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004724172 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10579059 Country of ref document: US Ref document number: 1020067009223 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004724172 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067009223 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 10579059 Country of ref document: US |